Business Wire

78 Per Cent of CSPs See Automation in Service Fulfillment as Key to Profitability

Share

HIGHLIGHTS:

  • CSPs missing USD 30 billion revenue opportunity in 2019 due to inadequate automation in fulfillment and sales, according to the second edition of the Create-Sell-Deliver Outlook
  • Only 25 per cent of delivery tasks that could be automated actually are today, with the bulk still being fulfilled manually, study shows
  • 78 per cent of communications service providers (CSPs) tie automation in service fulfillment to improved profitability
  • 150 respondents from CSPs worldwide surveyed for the study

CSPs worldwide are leaving money on the table as a result of missed automation opportunities in sales and service fulfillment, according to a new study from Sigma Systems.

Conducted in partnership with research consultancy Coleman Parkes Research, the second edition of the Create-Sell-Deliver Outlook surveyed operators worldwide to gauge their perception of product innovation and create-sell-deliver capabilities. Although 78 per cent of respondents recognized that automation in service fulfillment led to more profitable businesses, two-thirds said that the level of manual intervention had increased either slightly or significantly over the last two years.

While the survey found a belief that 14 per cent of fulfillment tasks would always be manual, it also revealed that of the remaining tasks which could be automated, just 25 per cent actually are today.

When asked to what extent a one per cent reduction in manual intervention would have on revenues1, respondents said there would be a two per cent gain – one per cent higher than last year’s result. This equates to USD 12 billion in additional revenues across tier-one and tier-two CSPs worldwide.

CSPs also see the value of automation beyond service fulfillment. Respondents said increasing automation of the configuration and quoting process could increase annual revenues by an average of three per cent – equating to USD 18 billion globally.

Stephen Krajewski, Director of Product Marketing, Sigma Systems, commented: “It is sobering that at a time when 5G technology, smart cities and the Internet of Everything are becoming a reality, CSPs do not have fully automated processes when increasing automation and reducing manual intervention would have a marked impact on their business. Improving revenues is a constant goal for CSPs, and at Sigma Systems our focus is to help our customers drive business transformation and product innovation by using catalog-driven systems to enable the most efficient end-to-end customer experience.”

For further information on the second edition of the Create-Sell-Deliver Outlook, go to https://sigma-systems.com/resource/whitepaper-the-create-sell-deliver-outlook-second-edition/, or contact us at info@sigma-systems.com.

About Coleman Parkes Research

Coleman Parkes Research is a UK-based and technology-focused B2B market research agency that specializes in highly targeted quantitative and qualitative research studies. Being both a data-driven provider and a data analytics company, the company’s research services have fuelled more than 2,000 projects to date, focusing on geographic regions across the world such as North America, South America, Central America, the UK, Continental Europe, the Middle East, Africa and the Asia-Pacific.

For more information, visit www.colemanparkes.com

About Sigma Systems (Twitter @SigmaSystems)

Sigma Systems is the global leader in catalog-driven software solutions for telecommunications, media and high-tech companies. It serves over 80 customers in 40 countries with its award-winning products. The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management, Provisioning, Insights and Portfolio Inventory products, and offers a core set of services including professional services, cloud services, and managed services. Sigma utilizes an agile approach to implementing its B/OSS products for its customers. Sigma has offices in North and South America, Europe and the Asia Pacific region, with technology and integration partners around the globe. Sigma is a Hansen Technologies company publicly listed on the Australian Stock Exchange – ASX:HSN.

Additional information can be found online at https://sigma-systems.com/

Visit Hansen Technologies at https://www.hansencx.com/


1 expressed as a percentage of current annual turnover

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Adnan Bashir
Senior Corporate Communications Manager
Sigma Systems
+1 647-204-0999

Chloe Purcell
Head of PR
Milner Strategic Marketing Ltd.
+44 1473 633123

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye